Anxiety and depression in people with hyperparathyroidism may be related to levels of 2 key hormones in the body, according to researchers.
Investigators assessed the relationship between intraoperative measurements obtained via laser speckle contrast imaging and outcomes following total thyroidectomy.
Patients on hemodialysis who have secondary hyperparathyroidism experienced a 40% reduction in PTH levels over 12 months of etelcalcetide treatment, investigators reported.
The goal of this study was to evaluate pregnancy outcome and total number of births in chronic hypoparathyroidism.
Weight loss partly accounted for the association between high parathyroid hormone levels and mortality among patients on hemodialysis.
Etelcalcetide use in patients with diabetic nephropathy might protect against development of adynamic bone disease, according to investigators.
In a large, single-center study, severe hypocalcemia developed in 1 in 4 patients who underwent total parathyroidectomy without autotransplantation.
A recently published report describes the case of a 61-year-old male patient who experienced antacid-induced hypercalcemia and highlights the importance of performing thorough medication reconciliation.
This report provides an update on the use of diagnostic tests for asymptomatic primary hyperparathyroidism in clinical practice.
Abrupt interruption or discontinuation of Natpara can result in severe hypocalcemia.
Parathyroidectomy may have a potential beneficial effect on lipid profiles and decrease cardiovascular risk in patients with primary hyperparathyroidism.